This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Dilated cardiomyopathyDilated Cardiomyopathy (DCM)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I42.0 | Special Copayment Reduction: V127 (5 years)
B. SynonymsIrreversible dilated cardiomyopathy, idiopathic DCM, congestive cardiomyopathy
C. Adult onsetLikelihood of first onset in adulthood high — mean onset in the 20s–50s; hereditary DCM also has high penetrance in adulthood, and pediatric onset is a minority
1. History1891 first described by Krehl → 1980 WHO classification established → 2000s discovery of TTN and LMNA → 2023 ESC guideline recommends genotype-specific treatment
2. CausesHereditary (~40%): TTN, LMNA, MYH7, SCN5A, etc.; non-hereditary: fibrosis after viral myocarditis, alcoholic, peripartum, toxic, etc.
3. GeneticsMore than 200 genes associated, including TTN (~25%, the most common), LMNA (malignant phenotype, conduction abnormalities, arrhythmias), MYH7, MYBPC3, PLN, SCN5A, and RBM20
4. General epidemiologyPrevalence 1/250–500; incidence 7/100,000 per year; 3rd leading cause of heart failure, most common cause of heart transplantation; male predominance 2.5:1
5. PathophysiologyAbnormal sarcomeric, cytoskeletal, and nuclear envelope proteins → cardiomyocyte death and fibrosis → left ventricular dilation and reduced contractility → reduced cardiac output and neurohormonal activation
6. SymptomsDyspnea, exercise intolerance, orthopnea, paroxysmal nocturnal dyspnea, leg edema, fatigue; palpitations and syncope (arrhythmia); thromboembolism
7. SignsCardiomegaly, S3 gallop, systolic murmur of valvular regurgitation; elevated jugular venous pressure; pulmonary crackles; pitting edema of the legs; LBBB and nonspecific ST changes on ECG
8. ScreeningEchocardiography (measurement of LVEDd and LVEF); BNP/NT-proBNP; ECG; screening echocardiography of first-degree relatives of patients with a family history (every 3–5 years)
9. DiagnosisEchocardiography (LVEF ≤ 45% + LVEDd > 2SD above normal); cardiac MRI (quantification of fibrosis and function); endomyocardial biopsy (to differentiate viral and specific myocarditis); gene panel
10. TreatmentGDMT: ACEi/ARB/ARNI + BB + MRA + SGLT2i; ICD (primary prevention); CRT-D (LBBB + QRS ≥ 150ms); LVAD; heart transplantation; LMNA DCM — early consideration of ICD
11. Prognosis5-year survival 50–70% (GDMT era); poor prognosis in LMNA DCM; considerable improvement when reverse remodeling is achieved; 5-year post-transplant survival about 75%
12. PreventionFamily screening (early initiation of GDMT); genetic counseling; correction of alcoholic and toxic causes of cardiomyopathy; prophylactic antiarrhythmics and ICD (LMNA and high-risk groups)
13. References10 references including the 2022 ACC/AHA HF guideline, the 2023 ESC Cardiomyopathy guideline, and key TTN/LMNA papers

1. History

The history of dilated cardiomyopathy (DCM) dates back to the late 19th century. In 1891, the German pathologist Ludolph Krehl (1861–1937) described cases of heart failure due to heart muscle disease of unknown cause and first classified them as "idiopathic myocardial disease". For decades afterward, dilated cardiomyopathy was called by various names — congestive cardiomyopathy, primary myocardial disease, and others — and was not clearly distinguished from ischemic or hypertensive heart disease.

In 1957, Dr. Brigid Wallace and colleagues systematically described cases of heart failure of non-ischemic cause in Africa, and subsequently W. Gordon Brigden (1957) proposed the concept of "non-coronary cardiomyopathy" in the United Kingdom. In 1961, Goodwin et al. defined cardiomyopathy as "primary cardiomyopathy" and established a system classifying it into three types — dilated, hypertrophic, and restrictive — which became the prototype of the current classification.

In 1980, the World Health Organization (WHO) and the International Society and Federation of Cardiology (ISFC) published an official classification of cardiomyopathies, defining dilated cardiomyopathy as a disease characterized by left ventricular (or biventricular) dilation and impaired systolic function. These classification criteria have since been revised several times. The revised 1995 WHO classification subdivided cardiomyopathies by functional type and also included secondary forms due to specific causes (viral, alcoholic, peripartum, etc.).

The period in which advances in molecular genetics revolutionized the understanding of DCM began in the 1990s. In 1994, the first DCM-related gene, dystrophin, was identified, followed by reports of MYH7 (β-myosin heavy chain) in 1999, LMNA (lamin A/C) in 2002, and TTN (titin) truncating variants (TTNtv) in 2012 as major causes of familial and sporadic DCM. In particular, TTNtv is the most common genetic cause, found in about 15–25% of all DCM, and the studies of Gerull et al. (2002) and Herman et al. (2012) were milestones.

In terms of treatment, the benefit of ACE inhibitors in heart failure was established in the 1980s (CONSENSUS trial, 1987), mortality reduction with beta-blockers was proven in the 1990s (COPERNICUS, MERIT-HF, CIBIS-II, etc.), spironolactone and eplerenone (MRAs) were added in the 2000s, ARNI (sacubitril/valsartan, PARADIGM-HF trial) came in 2014, and in 2020 SGLT2 inhibitors (dapagliflozin, DAPA-HF; empagliflozin, EMPEROR-Reduced) opened the era of four-drug therapy (GDMT: guideline-directed medical therapy). The 2023 European Society of Cardiology (ESC) cardiomyopathy guideline is the latest guideline specifying genotype-specific treatment strategies.


2. Causes

Dilated cardiomyopathy is classified by cause into hereditary (familial) and non-hereditary (acquired/environmental). In practice, genetic predisposition and environmental triggers often interact in combination.

Hereditary causes (~40%)

A genetic cause is identified in about 40% of patients traditionally classified as having idiopathic DCM. Autosomal dominant inheritance is the most common, and X-linked (dystrophin deficiency), autosomal recessive, and mitochondrial inheritance are also reported. The key causative genes are described in detail below. Familial DCM is defined as the presence of two or more patients with DCM in the same family.

Viral and inflammatory causes

After acute viral myocarditis, chronic myocardial damage and fibrosis may progress and transition to DCM. Known causative viruses include enteroviruses (Coxsackie B virus), adenovirus, parvovirus B19, Epstein-Barr virus, and CMV. Recently, DCM-like states due to myocardial injury after COVID-19 (SARS-CoV-2) infection have been reported. Autoimmune mechanisms (T-lymphocyte-mediated myocardial injury) cause persistent myocardial inflammation in some patients.

Toxic and drug-induced causes

Alcoholic cardiomyopathy: Myocardial toxicity from long-term heavy drinking (80 g or more per day for 5 years or more) accounts for about 10–15% of all DCM. There is also a reversible form in which LVEF can recover with abstinence. Cardiotoxicity of anticancer drugs: Anthracyclines (doxorubicin, etc.), cyclophosphamide, trastuzumab, and others cause myocardial damage. Illicit drugs such as cocaine and methamphetamine can also cause DCM.

Peripartum cardiomyopathy

DCM occurring in the last month of pregnancy or within 5 months after delivery, with an incidence of 1 per 1,000–4,000 pregnancies. Cardiotoxicity of the 16-kDa prolactin fragment, oxidative stress, and autoimmune mechanisms are involved. Bromocriptine (a prolactin inhibitor) shows benefit in some patients.

Tachycardia-induced cardiomyopathy

Myocardial dysfunction due to sustained tachycardia (atrial fibrillation, tachycardia, etc., mean heart rate > 100 beats/min, lasting weeks to months); LVEF can recover after correction of the tachycardia.


3. Genetics

The genetics of DCM has advanced rapidly over the past 20 years, and more than 200 genes have been reported to be associated with DCM. However, not all genes have the same level of evidence, and genes with clinically definitive evidence number about 10–20.

TTN (titin, 2q31.2) — the most common causative gene

Titin is the largest protein in the human body (~34,000 amino acids) and is essential for the elastic recoil and structural maintenance of the cardiac sarcomere. TTN truncating variants (TTNtv) — frameshift insertions/deletions, nonsense, and splice-site variants — are found in about 15–25% of all DCM and about 25% of familial DCM. TTNtv occurs in excess in DCM compared with healthy controls (about 1–2%), and TTNtv located in the A-band is particularly pathogenic. Features of TTNtv DCM: relatively favorable prognosis (high rate of reverse remodeling), good responsiveness to GDMT, and pregnancy acting as a trigger in women.

LMNA (lamin A/C, 1q22) — the most malignant phenotype

Lamin A/C (LMNA) is an intermediate filament protein forming the inner layer of the nuclear envelope and is involved in nuclear structural stability, regulation of gene expression, and DNA damage repair. LMNA variants are found in about 5–8% of DCM and are associated with the most malignant phenotype among DCMs. Features: atrial fibrillation, atrioventricular conduction abnormalities (first-degree AVB → complete AVB), and ventricular arrhythmias are prominent from early on, and arrhythmia-related events (sudden death, need for transplantation) occur before decline in exercise capacity. In LMNA DCM, ICD implantation is recommended early even at a stage when LVEF is relatively preserved (ESC 2023 guideline). LMNA is also a pleiotropic gene whose variants cause Emery-Dreifuss muscular dystrophy, lipodystrophy, and Werner syndrome-like progeroid syndromes.

MYH7, MYBPC3 (sarcomeric proteins)

Variants in MYH7 (β-myosin heavy chain, 14q11.2) and MYBPC3 (myosin-binding protein C, 11p11.2) are well known as causes of hypertrophic cardiomyopathy (HCM), but some variants cause DCM. In DCM, MYH7 variants are found in about 4–5% and MYBPC3 variants in about 2–4%. Even in the same gene, HCM or DCM phenotypes appear differently depending on variant type and location.

Other major genes

PLN (phospholamban, 6q22.31): a regulatory protein of the sarcoplasmic reticulum Ca²⁺-ATPase (SERCA2a). The PLN p.Arg14del variant accounts for 12% of DCM in the Dutch population and is associated with malignant arrhythmias. SCN5A (Nav1.5 sodium channel, 3p22.2): DCM with concurrent conduction abnormalities; overlapping phenotype with Brugada syndrome. RBM20 (RNA-binding motif protein 20, 10q25.2): about 2% of DCM, early onset and high risk of ventricular arrhythmias. FLNC (filamin C): DCM and ventricular arrhythmias; early consideration of ICD.


4. General epidemiology

Dilated cardiomyopathy is an important cause of heart failure and accounts for a substantial disease burden worldwide.

Prevalence and incidence

The prevalence of DCM in the general population is estimated at about 1/250–500 (0.2–0.4%). Some believe it may be higher than previous estimates owing to recent advances in imaging technology and genetic testing. The annual incidence is reported at about 7/100,000 per year, and about 500,000 people are newly diagnosed worldwide each year. Among the causes of heart failure, DCM ranks third after ischemic heart disease and hypertensive heart disease, and it is the most common single indication for heart transplantation worldwide.

Sex and age distribution

DCM occurs more often in males, at a ratio of about 2.5:1. Age at onset is most commonly in the 20s–50s, with a mean age at diagnosis of about 40–45 years. Onset in childhood and adolescence is possible, but adult onset predominates. Some hereditary forms (LMNA, TTN) show high penetrance in adulthood, with symptoms appearing in the 30s–50s.

Epidemiology in Korea

In DCM epidemiologic studies using Korean health insurance claims data, prevalence is reported at a level similar to Western countries. In a 2016–2021 Korean DCM hospitalization cohort, in-hospital mortality was 3.5–4.5%, the CRT/ICD implantation rate 15.3%, and heart transplantation 8.07%. A Korean registry of hereditary cardiomyopathies is being established, and the distribution of genetic variants in Koreans may differ in part from that in Western populations.


5. Pathophysiology

The common final pathway of DCM is a continuous process leading to cardiomyocyte loss, myocardial dysfunction, and extracellular matrix remodeling. The starting point of the molecular mechanism differs by cause, but all eventually converge on left ventricular dilation and impaired systolic function.

Mechanism of sarcomere dysfunction (MYH7, MYBPC3, TTN, etc.)

Sarcomeric protein variants reduce the ability of cardiomyocytes to generate and transmit contractile force. In TTNtv, the amount of functional titin protein expressed is reduced (haploinsufficiency), impairing passive elasticity of the sarcomere and support for active contraction. MYH7 DCM variants alter the kinetics of actin-myosin cross-bridges, reducing contractility. As compensatory responses to this reduced contractility, cardiomyocyte hypertrophy (eccentric hypertrophy), chamber dilation, and neurohormonal activation (RAAS, SNS) occur, and when these compensatory mechanisms are prolonged, they lead to cardiomyocyte death and fibrosis.

Mechanism of nuclear envelope dysfunction (LMNA)

Lamin A/C proteins in the inner layer of the nuclear envelope are involved in supporting nuclear structure, chromatin organization, and binding of signaling proteins. With LMNA variants, increased nuclear envelope fragility → nuclear damage from mechanical stress → activation of the DNA damage response → cardiomyocyte death. At the same time, LMNA variants lead to abnormal activation of the ERK1/2 and MAPK pathways, impaired mTOR and AMPK signaling, and abnormal expression of cardiac ion channels (Nav1.5, etc.), markedly increasing the predisposition to arrhythmias.

Abnormal calcium regulation and common pathways

Regardless of cause, abnormal calcium ion regulation is commonly observed in advanced DCM. Reduced expression and function of SERCA2a delay removal of cytosolic Ca²⁺, and ryanodine receptor (RyR2) leak causes cytosolic Ca²⁺ overload. This causes reduced myocardial contractility and arrhythmias (afterdepolarizations, EAD/DAD). As cardiomyocyte loss accumulates, cardiac fibroblast activation → TGF-β pathway → collagen deposition → myocardial interstitial fibrosis progresses, and fibrosis causes increased ventricular stiffness and electrical conduction abnormalities.

Neurohormonal vicious cycle

Reduced cardiac output → activation of the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) → increased heart rate, vasoconstriction, and fluid retention (compensation) → increased myocardial oxygen demand, increased afterload, and cardiomyocyte toxicity (direct toxicity of norepinephrine, angiotensin II, and aldosterone) → a vicious cycle of further myocardial damage forms. Blocking this neurohormonal vicious cycle is the core principle of GDMT (ACEi/ARB/ARNI, BB, MRA).


6. Symptoms

The symptoms of DCM result mainly from reduced forward cardiac output (forward failure) and increased backward hydrostatic pressure (backward failure) due to impaired left ventricular (or biventricular) systolic function.

Heart failure symptoms

Dyspnea is the most common symptom of DCM. Initially it appears only with exertion, such as climbing stairs or walking briskly, but as the disease progresses, dyspnea appears with daily activities and eventually at rest. Orthopnea: dyspnea that worsens on lying down, reflecting increased pulmonary venous pressure; patients need to raise the head of the bed or sleep sitting up. Paroxysmal nocturnal dyspnea: suddenly waking from sleep short of breath, caused by a surge in pulmonary congestion from redistribution of leg edema fluid in the supine position. Exercise intolerance and fatigue: fatigue, muscle weakness, and reduced concentration appear due to inadequate tissue oxygen delivery from reduced cardiac output. Leg edema: pitting edema of the ankles and legs develops due to fluid and sodium retention from right heart failure or RAAS activation. Ascites and early satiety (ascites, hepatomegaly) are also symptoms of right heart failure.

Arrhythmia-related symptoms

Palpitations: caused by various arrhythmias such as atrial fibrillation, premature ventricular contractions, and ventricular tachycardia. In DCM, atrial fibrillation occurs as a complication in about 25–30%, and heart failure and atrial fibrillation form a vicious cycle, each worsening the other. Syncope or presyncope: caused by ventricular tachycardia or fibrillation or by high-grade atrioventricular block (of particular concern in LMNA DCM); it is a warning symptom of sudden death. In LMNA DCM, syncope may occur even when LVEF is relatively preserved, requiring caution.

Thromboembolic symptoms

Blood stasis within the dilated left ventricle and atrial fibrillation can lead to intracardiac thrombus (LV thrombus) formation and systemic embolism (stroke, mesenteric embolism, renal infarction, etc.). The risk of left ventricular thrombus is particularly high in patients with very low LVEF (< 20%).


7. Signs

On physical examination, the signs of DCM vary with the degree of heart failure and the predominant pathology (left-sided, right-sided, or biventricular).

Cardiac findings

Inferolateral displacement and enlargement of the apical impulse (PMI) (reflecting cardiomegaly). Third heart sound (S3 gallop): a low-frequency sound arising from the dilated ventricle during early diastolic ventricular filling; a specific finding of severe left ventricular dysfunction (low sensitivity but high specificity). Systolic murmur of mitral regurgitation: a holosystolic murmur heard at the apex due to functional mitral regurgitation from mitral annular dilation, papillary muscle displacement, and the like caused by left ventricular dilation. An accentuated P2 is also observed when pulmonary hypertension is present.

Signs of heart failure

Elevated jugular venous pressure (JVP): reflects increased right atrial pressure; pulsatile venous distension is observed at the anterior border of the sternocleidomastoid. Hepatojugular reflux is also positive. Pulmonary crackles: reflect pulmonary edema from left heart failure, with end-inspiratory crackles especially in both lower lung fields. Pitting edema of the legs: symmetric pitting edema, mainly at the ankles and shins. Blood pressure shows a low pulse pressure and hypotension, and cool extremities and cyanosis (severe low cardiac output) are also possible.

ECG findings

Nonspecific ST-T changes, left ventricular hypertrophy (LVH) pattern, left bundle branch block (LBBB) (occurring in about 25–30%, an indication for CRT), atrial fibrillation, PR prolongation and high-grade atrioventricular block (characteristic of LMNA DCM), sustained ventricular tachycardia.


8. Screening

Screening for DCM consists of early detection in asymptomatic high-risk groups (family members, carriers of genetic variants) and a rapid diagnostic pathway for symptomatic patients.

Family screening

Regular screening of first-degree relatives (parents, siblings, children) of patients diagnosed with DCM is recommended to detect asymptomatic DCM or early cardiac dysfunction. Screening methods: echocardiography (left ventricular size, LVEF) + 12-lead ECG + symptom history. Screening starts in adulthood (age 18 and over) and is recommended to be repeated every 3–5 years. When high-risk gene variants such as LMNA or RBM20 are identified, follow-up is more frequent (every 1–2 years).

Serum biomarkers

BNP or NT-proBNP: natriuretic peptides secreted in response to ventricular wall stress, used to assess the presence and severity of heart failure and to follow treatment response. NT-proBNP ≥ 125 pg/mL is the screening threshold for heart failure. Troponin (TnI/TnT): assesses acute worsening and the extent of cardiomyocyte injury. Repeated elevation is a marker of poor prognosis.

Echocardiography

Echocardiography is the key tool for screening and diagnosis of DCM. It includes measurement of left ventricular end-diastolic diameter (LVEDd) (upper limit of normal: men > 60 mm, women > 54 mm, or indexed to body surface area), measurement of LVEF (< 45% threshold), presence of regional wall motion abnormalities (to differentiate ischemic causes), assessment of mitral regurgitation, and estimation of pulmonary artery pressure.


9. Diagnosis

Diagnosis of DCM consists of objectively confirming left ventricular dilation and impaired systolic function and excluding secondary causes (coronary artery disease, valvular disease, hypertension, toxins, etc.).

Echocardiographic diagnostic criteria

Diagnostic criteria for DCM (WHO/ESC): in the absence of an ischemic cause, left ventricular dilation (LVEDd > 2SD above the normal value indexed to body surface area) and LVEF ≤ 45%. When wall motion abnormalities are present, exclusion of coronary artery disease is mandatory. LVEF is measured more accurately with 3D echocardiography or cardiac MRI.

Cardiac MRI (CMR)

CMR is very useful for diagnosing DCM and differentiating its causes. Late gadolinium enhancement (LGE): pattern analysis of myocardial fibrosis (mid-wall linear LGE is specific to DCM, while subendocardial LGE suggests an ischemic origin). The presence and extent of LGE are independent predictors of ventricular arrhythmia and sudden death risk. T1 mapping and ECV (extracellular volume fraction): quantification of diffuse myocardial fibrosis. CMR is also used for accurate quantification of LVEF and RV function and for assessment of myocardial inflammation (T2-weighted imaging).

Endomyocardial biopsy

Endomyocardial biopsy is not recommended for routine diagnosis of DCM, but is performed in rapidly progressive heart failure when differentiation of giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, or amyloidosis is needed. It is accompanied by immunohistochemistry, electron microscopy, and viral PCR testing.

Gene panel testing

In idiopathic or familial DCM, the ESC 2023 guideline recommends testing with a comprehensive cardiomyopathy gene panel (40–80 genes including TTN, LMNA, MYH7, MYBPC3, SCN5A, PLN, RBM20). When a pathogenic variant is identified, cascade genetic testing of the family is recommended.


10. Treatment

The core goals of DCM treatment are to slow heart failure progression, prevent sudden death, and improve symptoms. Guideline-directed medical therapy (GDMT) is the foundation for improving prognosis.

Guideline-directed medical therapy (GDMT)

Four-drug combination therapy is currently the standard for HFrEF (LVEF ≤ 40%). ① ACE inhibitor (ACEi)/ARB or ARNI (sacubitril/valsartan, Entresto): significantly reduces mortality and readmission through RAAS inhibition. ARNI demonstrated an additional mortality reduction compared with ACEi (PARADIGM-HF, LVEF ≤ 35%). ② Beta-blockers (BB): carvedilol, bisoprolol, and metoprolol (CR/XL) demonstrated mortality reduction in HFrEF. ③ Mineralocorticoid receptor antagonists (MRA): spironolactone and eplerenone reduce mortality and improve LVEF. ④ SGLT2 inhibitors: dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) significantly reduced heart failure hospitalization and cardiovascular death in HFrEF (regardless of ischemic status).

ICD and CRT

ICD (implantable cardioverter-defibrillator): primary prevention ICD implantation is indicated when LVEF ≤ 35% persists despite 3 months or more of GDMT (ACC/AHA Class I). LMNA DCM: even when LVEF is relatively preserved, early ICD is considered when high-risk arrhythmia criteria (ventricular tachycardia, atrioventricular block, atrial fibrillation, male sex, non-truncating variant) are present. CRT-D (cardiac resynchronization therapy): strongly recommended for LVEF ≤ 35% + LBBB + QRS ≥ 150ms + NYHA II–IV (reduces mortality, improves symptoms, induces reverse remodeling). With QRS 120–149ms, CRT is considered in the presence of LBBB.

Mechanical circulatory support and heart transplantation

LVAD (left ventricular assist device): for end-stage heart failure despite maximal GDMT (bridge-to-transplantation while awaiting heart transplantation, or destination therapy in transplant-ineligible patients). Modern centrifugal LVADs (HeartMate 3, etc.) show 2-year survival of 77%. Heart transplantation (Cardiac Transplantation): DCM is the most common single indication for heart transplantation worldwide. Indications: NYHA III–IV despite optimal therapy, 6MWT < 300m, peak VO2 < 10–12 mL/kg/min. Post-transplant survival is about 85% at 1 year, about 75% at 5 years, and about 55% at 10 years.

Genotype-specific treatment

LMNA DCM: prophylactic ICD, monitoring, and aggressive arrhythmia management. TTN DCM: good response to GDMT; monitoring of reverse remodeling; preconception counseling (risk of peripartum worsening). Mavacamten is an HCM-specific drug and is at the clinical trial stage in DCM.


11. Prognosis

The prognosis of DCM has improved markedly compared with before the introduction of GDMT, but long-term mortality remains substantial.

Survival

In studies before GDMT (1980s–90s), 1-year mortality of DCM was about 20–30% and 5-year mortality 50–60%, which was very poor. Since the introduction of GDMT, 5-year survival has now improved to about 50–70%, reflecting the combined effects of neurohormonal blockade (ACEi/ARB, BB, MRA) and device therapy (ICD, CRT). However, even with optimal GDMT, the 2-year mortality of patients hospitalized for heart failure still reaches 20–30%.

Reverse remodeling

On follow-up echocardiography 3–6 months after starting GDMT, "reverse remodeling", in which LVEF rises significantly (> 10–15 percentage points) and normalizes, is observed in some (about 25–40%) patients. Patients who achieve reverse remodeling have a markedly improved long-term prognosis, and ICD reassessment is also considered. TTNtv DCM has a relatively high rate of reverse remodeling, whereas LMNA DCM and cases with extensive myocardial LGE have low rates.

Prognosis by genotype

LMNA DCM: poorest prognosis; high rate of transplantation or death within 5 years; sudden death risk independent of LVEF. TTNtv DCM: relatively favorable prognosis; high rate of achieving reverse remodeling. PLN p.Arg14del DCM: high risk of malignant arrhythmias (Dutch cohort). Main causes of death: progressive heart failure, sudden cardiac death (ventricular fibrillation/tachycardia), stroke.


12. Prevention

Prevention strategies for DCM require a tailored approach to both genetic and acquired causes.

Family screening and genetic counseling

The key is early detection of asymptomatic DCM or borderline reduced LVEF through echocardiographic screening of all first-degree relatives of patients diagnosed with DCM. When a pathogenic gene variant (TTN, LMNA, MYH7, etc.) is identified, more intensive follow-up (echocardiography every 1–2 years) is recommended for relatives who carry the variant. In collaboration with genetic counseling professionals, information on reproductive options (prenatal genetic diagnosis, preimplantation diagnosis, etc.) is provided.

Correction of acquired causes

Alcoholic cardiomyopathy: partial recovery of cardiac function is possible with complete abstinence. Anticancer drug cardiotoxicity: baseline echocardiography before anthracycline use, echocardiographic follow-up during use, minimization of cardiotoxicity (use of dexrazoxane, divided dosing, choice of liposomal formulations). Peripartum cardiomyopathy: identification of high-risk mothers (history of previous peripartum cardiomyopathy, hypertension during pregnancy), consideration of a prolactin suppression (bromocriptine) strategy.

Prophylactic antiarrhythmic treatment

In high-risk hereditary forms such as LMNA DCM and FLNC or RBM20 variants, early ICD implantation is considered even before the LVEF threshold (≤ 35%) is reached. Evidence that early rhythm control of atrial fibrillation (rhythm control strategy) helps prevent worsening heart failure (EAST-AFNET 4, etc.) is also considered.


13. References

  1. Herman DS, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619–628. PMID: 22335739
  2. Taylor MR, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. 2003;41(5):771–780. PMID: 12628718
  3. Hershberger RE, et al. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531–547. PMID: 23900355
  4. McMurray JJ, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004. PMID: 25176015
  5. McMurray JJ, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995–2008. PMID: 31535829
  6. Merlo M, et al. Reverse remodeling after optimised therapy in dilated cardiomyopathy. J Am Coll Cardiol. 2011;58(12):1263–1273. PMID: 21903058
  7. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
  8. Arbelo E, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503–3626. doi:10.1093/eurheartj/ehad194
  9. Fatkin D, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341(23):1715–1724. PMID: 10580070
  10. Pinto YM, et al. Proposal for a revised definition of dilated cardiomyopathy. Eur Heart J. 2016;37(23):1850–1858. doi:10.1093/eurheartj/ehv727